Evaluating localized prostate cancer and identifying candidates for focal therapy. Read more about Evaluating localized prostate cancer and identifying candidates for focal therapy.
Conventional treatments of localized prostate cancer. Read more about Conventional treatments of localized prostate cancer.
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Read more about Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Outcomes and cost analysis of pyeloplasty for antenatally diagnosed ureteropelvic junction obstruction using Markov models. Read more about Outcomes and cost analysis of pyeloplasty for antenatally diagnosed ureteropelvic junction obstruction using Markov models.
Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Read more about Clinical events in prostate cancer lifestyle trial: results from two years of follow-up.
Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Read more about Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure.
Is robotic radical cystectomy an appropriate treatment for bladder cancer? Short-term oncologic and clinical follow-up in 50 consecutive patients. Read more about Is robotic radical cystectomy an appropriate treatment for bladder cancer? Short-term oncologic and clinical follow-up in 50 consecutive patients.
Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Read more about Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer.
Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Read more about Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Read more about p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
